Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
34.07
-1.74 (-4.86%)
At close: Sep 9, 2026, 4:00 PM EDT
34.07
0.00 (0.00%)
After-hours: Sep 9, 2026, 4:10 PM EDT
Alto Neuroscience Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
68
Market Cap
1.34B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 210.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MeiraGTx Holdings | 397.50M |
| Omeros | 38.42M |
| Maze Therapeutics | 20.00M |
| Alumis | 7.40M |
| Odyssey Therapeutics | 99.00K |
ANRO News
- 8 hours ago - Alto Neuroscience Announces Participation in Upcoming Investor Conferences - Business Wire
- 13 days ago - Alto Neuroscience names Nick Smith president, CFO - TheFly
- 13 days ago - Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer - Business Wire
- 23 days ago - Alto Neuroscience price target raised to $55 from $50 at H.C. Wainwright - TheFly
- 23 days ago - Alto Neuroscience reports Q EPS (65c), consensus (77c) - TheFly
- 23 days ago - Alto Neuroscience price target raised to $37 from $28 at BTIG - TheFly
- 24 days ago - Alto Neuroscience price target raised to $37 from $33 at BofA - TheFly
- 4 weeks ago - Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Business Wire